PHARMACOKINETIC AND ORAL BIOAVAILABILITY STUDIES IN RATS

大鼠药代动力学和口服生物利用度研究

• 批准号: 10943488
• 负责人: JAN BEUMER
• 金额: $ 4.5万
• 依托单位: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-25 至 2024-09-24
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10943488
• 关键词: Authorization documentation; Biological Assay; Biological Availability; Blood; Chemical Structure; Chromatography; Collection; Contractor; Contracts; Data; Data Analyses; Dose; Drug Kinetics; Exercise; Formulation; Hemorrhage; High Pressure Liquid Chromatography; Laboratories; Methods; Modeling; Modification; Molecular Weight; Oral; Plasma; Procedures; Property; Protocols documentation; Rattus; Route; Sampling; Solubility; Testing; Time; Validation; Visual; analytical method; anti-cancer; authority; base; cost estimate; design; drug candidate; drug-like compound

The purpose of this task order is to identify suitable formulations for administration of potential drug candidates to rats for early pharmacokinetic studies and to characterize the plasma pharmacokinetics (PK) and bioavailability of anticancer compounds in rats. Chemical structures, molecular weight (MW), and other available properties of test agents will be provided and should be used to provide guidance on formulation approaches (e.g., pH-adjustment, co-solvents). Route and dose level (mg/kg) targets will be provided. There will be a base period and optional tasks included under this task order. The base period will provide for formulation optimization/solubility assessment and one (1) rat pharmacokinetic study with one (1) compound.

该任务顺序的目的是确定适合对大鼠进行早期药代动力学研究的潜在药物候选物的配方，并表征大鼠抗癌化合物的血浆药代动力学（PK）和生物利用度。将提供化学结构，分子量（MW）和其他测试剂的其他可用特性，应用于提供有关配方方法的指导（例如，pH值调整，共溶剂）。 将提供路线和剂量水平（mg/kg）目标。 此任务订单下将有一个基本周期和可选任务。 基本周期将提供配方优化/溶解度评估，并具有一（1）个化合物的一（1）个大鼠药代动力学研究。